Why Is ARROWHEAD PHARMACEUT (ARWR) Stock Moving Today?

Why ARWR stock is up today

Arrowhead Pharmaceuticals stock surged nearly 19% to $88.70 on Monday, marking its best one-day gain in nearly eight months. The rally was driven by positive Phase 3 trial results for its lipid-lowering drug plozasiran and an analyst upgrade from Chardan Capital. The stock closed at a 52-week high, reflecting renewed investor confidence in the company's pipeline and potential for broader FDA approval.

What Happened

Arrowhead announced positive topline results from two Phase 3 studies evaluating plozasiran for the treatment of hypertriglyceridemia. The results showed significant reductions in triglyceride levels, with one trial achieving 79-81% reductions. These findings were described as a "derisking event" by analysts, reducing regulatory and commercial uncertainties. Chardan analyst Keay Nakae raised the firm's price target on Arrowhead to $115 from $90 and maintained a Buy rating. The analyst cited the strong data and the company's competitive position against peers like Ionis as key catalysts. The stock's surge also coincided with a webcast scheduled for August 4, 2026, where the company will provide further insights into its pipeline and strategic direction.

What The Data Shows

The stock's intraday movement showed a sharp upward trend, closing near the session high. The move pushed Arrowhead to a 52-week high of $88.70, just above its previous peak of $87.83. The company's market cap now stands at $10.5 billion, despite remaining unprofitable with a trailing twelve-month EPS of -2.17. Revenue has grown by 14.1% TTM, but the net margin remains negative at -48.4%. Unusual options activity included a notable put premium of $560K, indicating some bearish positioning. Recent insider transactions show one director sold $228K in shares, while a major congressional trade reported a sale of $100,001-$250,000.

What To Watch

Investors should monitor the scheduled webcast on August 4, 2026, for further updates on Arrowhead's pipeline and strategic direction. The company's upcoming regulatory filings and any additional Phase 3 data will be key to sustaining the recent momentum.